Veramyst Patent Expiration

Veramyst is a drug owned by Glaxosmithkline. It is protected by 8 US drug patents filed from 2013 to 2016. Out of these, 4 drug patents are active and 4 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 01, 2027. Details of Veramyst's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8347879 Fluid dispensing device
Apr, 2027

(2 years from now)

Active
US8062264 Fluid dispensing device
Apr, 2026

(1 year, 4 months from now)

Active
US8752543 Fluid dispensing device
Apr, 2026

(1 year, 4 months from now)

Active
US8147461 Fluid dispensing device
Mar, 2025

(3 months from now)

Active
US9320862 Fluid dispensing device
Nov, 2024

(26 days ago)

Expired
US7541350 Formulation containing anti-inflammatory androstane derivative
Aug, 2021

(3 years ago)

Expired
US6858596 Formulation containing anti-inflammatory androstane derivative
Aug, 2021

(3 years ago)

Expired
US7101866 Anti-inflammatory androstane derivative
Aug, 2021

(3 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Veramyst is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Veramyst's family patents as well as insights into ongoing legal events on those patents.

Veramyst's Family Patents

Veramyst has patent protection in a total of 23 countries. It's US patent count contributes only to 7.0% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Veramyst.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Veramyst's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 01, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Veramyst Generics:

There are no approved generic versions for Veramyst as of now.

Alternative Brands for Veramyst

Veramyst which is used for relieving symptoms of seasonal and perennial allergic rhinitis in patients 2 years of age and older., has several other brand drugs using the same active ingredient (Fluticasone Furoate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Glaxo Grp Ltd
Breo Ellipta
Glaxosmithkline
Arnuity Ellipta
Trelegy Ellipta
Haleon Us Holdings
Flonase Sensimist Allergy Relief






About Veramyst

Veramyst is a drug owned by Glaxosmithkline. It is used for relieving symptoms of seasonal and perennial allergic rhinitis in patients 2 years of age and older. Veramyst uses Fluticasone Furoate as an active ingredient. Veramyst was launched by Glaxosmithkline in 2007.

Approval Date:

Veramyst was approved by FDA for market use on 27 April, 2007.

Active Ingredient:

Veramyst uses Fluticasone Furoate as the active ingredient. Check out other Drugs and Companies using Fluticasone Furoate ingredient

Treatment:

Veramyst is used for relieving symptoms of seasonal and perennial allergic rhinitis in patients 2 years of age and older.

Dosage:

Veramyst is available in spray, metered form for nasal use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.0275MG/INH SPRAY, METERED Prescription NASAL